

Viktor Umansky

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7304637/publications.pdf>

Version: 2024-02-01

103
papers

10,886
citations

43973

48
h-index

33814

99
g-index

108
all docs

108
docs citations

108
times ranked

15865
citing authors

#	ARTICLE	IF	CITATIONS
1	ADCK2 Knockdown Affects the Migration of Melanoma Cells via MYL6. <i>Cancers</i> , 2022, 14, 1071.	1.7	11
2	STAT3 inhibitor Napabucasin abrogates MDSC immunosuppressive capacity and prolongs survival of melanoma-bearing mice. , 2022, 10, e004384.		21
3	IL-6 as a major regulator of MDSC activity and possible target for cancer immunotherapy. <i>Cellular Immunology</i> , 2021, 359, 104254.	1.4	141
4	Potential therapeutic effect of low-dose paclitaxel in melanoma patients resistant to immune checkpoint blockade: A pilot study. <i>Cellular Immunology</i> , 2021, 360, 104274.	1.4	8
5	Blocking Migration of Polymorphonuclear Myeloid-Derived Suppressor Cells Inhibits Mouse Melanoma Progression. <i>Cancers</i> , 2021, 13, 726.	1.7	20
6	NASH limits anti-tumour surveillance in immunotherapy-treated HCC. <i>Nature</i> , 2021, 592, 450-456.	13.7	649
7	<scp>FOXD1</scp> promotes dedifferentiation and targeted therapy resistance in melanoma by regulating the expression of connective tissue growth factor. <i>International Journal of Cancer</i> , 2021, 149, 657-674.	2.3	14
8	Neutrophils in Tumorigenesis: Missing Targets for Successful Next Generation Cancer Therapies?. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6744.	1.8	15
9	Tumor promoting capacity of polymorphonuclear myeloid-derived suppressor cells and their neutralization. <i>International Journal of Cancer</i> , 2021, 149, 1628-1638.	2.3	16
10	Depletion and Maturation of Myeloid-Derived Suppressor Cells in Murine Cancer Models. <i>Methods in Molecular Biology</i> , 2021, 2236, 67-75.	0.4	2
11	Tumor-Derived Factors Differentially Affect the Recruitment and Plasticity of Neutrophils. <i>Cancers</i> , 2021, 13, 5082.	1.7	8
12	Involvement of platelet-derived VWF in metastatic growth of melanoma in the brain. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab175.	0.4	1
13	SOX2 in development and cancer biology. <i>Seminars in Cancer Biology</i> , 2020, 67, 74-82.	4.3	186
14	Mithramycin A and Mithralog EC-8042 Inhibit SETDB1 Expression and Its Oncogenic Activity in Malignant Melanoma. <i>Molecular Therapy - Oncolytics</i> , 2020, 18, 83-99.	2.0	21
15	IL-6 regulates CCR5 expression and immunosuppressive capacity of MDSC in murine melanoma. , 2020, 8, e000949.		59
16	Myeloid Cell Modulation by Tumor-Derived Extracellular Vesicles. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6319.	1.8	26
17	Differential expansion of circulating human MDSC subsets in patients with cancer, infection and inflammation. , 2020, 8, e001223.		104
18	Eosinophil accumulation predicts response to melanoma treatment with immune checkpoint inhibitors. <i>Oncolmmunology</i> , 2020, 9, 1727116.	2.1	52

#	ARTICLE	IF	CITATIONS
19	T-type calcium channel inhibition restores sensitivity to MAPK inhibitors in de-differentiated and adaptive melanoma cells. <i>British Journal of Cancer</i> , 2020, 122, 1023-1036.	2.9	20
20	Dormant tumor cells interact with memory CD8+ T cells in RET transgenic mouse melanoma model. <i>Cancer Letters</i> , 2020, 474, 74-81.	3.2	12
21	Enhanced expression of CD39 and CD73 on T cells in the regulation of anti-tumor immune responses. <i>OncoImmunology</i> , 2020, 9, 1744946.	2.1	37
22	Modern Aspects of Immunotherapy with Checkpoint Inhibitors in Melanoma. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2367.	1.8	34
23	Perspective “Escape from destruction: how cancer-derived EVs are protected from phagocytosis. <i>Trillium Extracellular Vesicles</i> , 2020, 2, 60-64.	0.1	2
24	A universal anti-cancer vaccine: Chimeric invariant chain potentiates the inhibition of melanoma progression and the improvement of survival. <i>International Journal of Cancer</i> , 2019, 144, 909-921.	2.3	5
25	Interactions among myeloid regulatory cells in cancer. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 645-660.	2.0	42
26	Melanoma Extracellular Vesicles Generate Immunosuppressive Myeloid Cells by Upregulating PD-L1 via TLR4 Signaling. <i>Cancer Research</i> , 2019, 79, 4715-4728.	0.4	97
27	ADP secreted by dying melanoma cells mediates chemotaxis and chemokine secretion of macrophages via the purinergic receptor P2Y12. <i>Cell Death and Disease</i> , 2019, 10, 760.	2.7	18
28	Tumor-Specific Regulatory T Cells from the Bone Marrow Orchestrate Antitumor Immunity in Breast Cancer. <i>Cancer Immunology Research</i> , 2019, 7, 1998-2012.	1.6	18
29	Deciphering myeloid-derived suppressor cells: isolation and markers in humans, mice and non-human primates. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 687-697.	2.0	168
30	Histone methyltransferase SETDB1 contributes to melanoma tumorigenesis and serves as a new potential therapeutic target. <i>International Journal of Cancer</i> , 2019, 145, 3462-3477.	2.3	46
31	Targeting the Post-Irradiation Tumor Microenvironment in Glioblastoma via Inhibition of CXCL12. <i>Cancers</i> , 2019, 11, 272.	1.7	15
32	Complex Formation with Monomeric β -Tubulin and Importin 13 Fosters c-Jun Protein Stability and Is Required for c-Jun TM s Nuclear Translocation and Activity. <i>Cancers</i> , 2019, 11, 1806.	1.7	6
33	Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression. <i>British Journal of Cancer</i> , 2019, 120, 16-25.	2.9	504
34	Opposing roles of eosinophils in cancer. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 823-833.	2.0	86
35	Fighting infant infections with myeloid-derived suppressor cells. <i>Journal of Clinical Investigation</i> , 2019, 129, 4080-4082.	3.9	5
36	Metformin blocks myeloid-derived suppressor cell accumulation through AMPK-DACH1-CXCL1 axis. <i>OncoImmunology</i> , 2018, 7, e1442167.	2.1	67

#	ARTICLE	IF	CITATIONS
37	Optimized dendritic cell vaccination induces potent CD8 T cell responses and anti-tumor effects in transgenic mouse melanoma models. <i>Oncolmmunology</i> , 2018, 7, e1445457.	2.1	13
38	Circulating and Tumor Myeloid-derived Suppressor Cells in Resectable Nonâ€“Small Cell Lung Cancer. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 198, 777-787.	2.5	129
39	Editorial: Two MDSC faces in obesity: Correcting metabolic dysfunctions but promoting tumor development. <i>Journal of Leukocyte Biology</i> , 2018, 103, 373-375.	1.5	2
40	CCR5+ Myeloid-Derived Suppressor Cells Are Enriched and Activated in Melanoma Lesions. <i>Cancer Research</i> , 2018, 78, 157-167.	0.4	127
41	The role of hypoxia in shaping the recruitment of proangiogenic and immunosuppressive cells in the tumor microenvironment. <i>Wspolczesna Onkologia</i> , 2018, 2018, 7-13.	0.7	23
42	Targeting SOX2 in anticancer therapy. <i>Expert Opinion on Therapeutic Targets</i> , 2018, 22, 983-991.	1.5	60
43	Targeting Myeloid-Derived Suppressor Cells to Bypass Tumor-Induced Immunosuppression. <i>Frontiers in Immunology</i> , 2018, 9, 398.	2.2	354
44	Myeloid-Derived Suppressor Cells Hinder the Anti-Cancer Activity of Immune Checkpoint Inhibitors. <i>Frontiers in Immunology</i> , 2018, 9, 1310.	2.2	404
45	Loss of neural crestâ€“associated gene <i>FOXD1</i> impairs melanoma invasion and migration <i>via</i> <i>RAC1B</i> downregulation. <i>International Journal of Cancer</i> , 2018, 143, 2962-2972.	2.3	25
46	SOX2â€“mediated upregulation of CD24 promotes adaptive resistance toward targeted therapy in melanoma. <i>International Journal of Cancer</i> , 2018, 143, 3131-3142.	2.3	66
47	Tumor-derived microRNAs induce myeloid suppressor cells and predict immunotherapy resistance in melanoma. <i>Journal of Clinical Investigation</i> , 2018, 128, 5505-5516.	3.9	193
48	Identification of inhibitors of myeloid-derived suppressor cells activity through phenotypic chemical screening. <i>Oncolmmunology</i> , 2017, 6, e1258503.	2.1	12
49	CCR5 in recruitment and activation of myeloid-derived suppressor cells in melanoma. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 1015-1023.	2.0	68
50	Melanoma-Derived iPCCs Show Differential Tumorigenicity and Therapy Response. <i>Stem Cell Reports</i> , 2017, 8, 1379-1391.	2.3	33
51	Tadalafil has biologic activity in human melanoma. Results of a pilot trial with <i>Tadalafil</i> in patients with metastatic Melanoma (TaMe). <i>Oncolmmunology</i> , 2017, 6, e1326440.	2.1	74
52	CCR5 Directs the Mobilization of CD11b+Gr1+Ly6Clow Polymorphonuclear Myeloid Cells from the Bone Marrow to the Blood to Support Tumor Development. <i>Cell Reports</i> , 2017, 21, 2212-2222.	2.9	83
53	Myeloid-derived suppressor cells and tumor escape from immune surveillance. <i>Seminars in Immunopathology</i> , 2017, 39, 295-305.	2.8	63
54	Heparins that block VEGF-A-mediated von Willebrand factor fiber generation are potent inhibitors of hematogenous but not lymphatic metastasis. <i>Oncotarget</i> , 2016, 7, 68527-68545.	0.8	33

#	ARTICLE	IF	CITATIONS
55	The Role of Myeloid-Derived Suppressor Cells (MDSC) in Cancer Progression. <i>Vaccines</i> , 2016, 4, 36.	2.1	296
56	Directed Dedifferentiation Using Partial Reprogramming Induces Invasive Phenotype in Melanoma Cells. <i>Stem Cells</i> , 2016, 34, 832-846.	1.4	27
57	T-Cell Therapy Enabling Adenoviruses Coding for IL2 and TNF α Induce Systemic Immunomodulation in Mice With Spontaneous Melanoma. <i>Journal of Immunotherapy</i> , 2016, 39, 343-354.	1.2	21
58	Ret mouse very large tumors (VLTs) display altered ratios of infiltrating memory to naive T cells: Roles in tumor expansion. <i>Pathophysiology</i> , 2016, 23, 211-220.	1.0	1
59	Macrophage-derived nitric oxide initiates T-cell diapedesis and tumor rejection. <i>Oncolmmunology</i> , 2016, 5, e1204506.	2.1	45
60	Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. <i>Nature Communications</i> , 2016, 7, 12150.	5.8	2,076
61	Incipient Melanoma Brain Metastases Instigate Astrogliosis and Neuroinflammation. <i>Cancer Research</i> , 2016, 76, 4359-4371.	0.4	81
62	mRNA-based dendritic cell immunization improves survival in ret transgenic mouse melanoma model. <i>Oncolmmunology</i> , 2016, 5, e1160183.	2.1	4
63	Predictive immune markers in advanced melanoma patients treated with ipilimumab. <i>Oncolmmunology</i> , 2016, 5, e1158901.	2.1	23
64	Chemokine receptor patterns in lymphocytes mirror metastatic spreading in melanoma. <i>Journal of Clinical Investigation</i> , 2016, 126, 921-937.	3.9	71
65	Elevated chronic inflammatory factors and myeloid-derived suppressor cells indicate poor prognosis in advanced melanoma patients. <i>International Journal of Cancer</i> , 2015, 136, 2352-2360.	2.3	142
66	von Willebrand factor fibers promote cancer-associated platelet aggregation in malignant melanoma of mice and humans. <i>Blood</i> , 2015, 125, 3153-3163.	0.6	110
67	Diminished levels of the soluble form of RAGE are related to poor survival in malignant melanoma. <i>International Journal of Cancer</i> , 2015, 137, 2607-2617.	2.3	28
68	Extracellular vesicle-mediated transfer of functional RNA in the tumor microenvironment. <i>Oncolmmunology</i> , 2015, 4, e1008371.	2.1	227
69	Characterization of myeloid leukocytes and soluble mediators in pancreatic cancer: importance of myeloid-derived suppressor cells. <i>Oncolmmunology</i> , 2015, 4, e998519.	2.1	89
70	Myeloid Cells and Related Chronic Inflammatory Factors as Novel Predictive Markers in Melanoma Treatment with Ipilimumab. <i>Clinical Cancer Research</i> , 2015, 21, 5453-5459.	3.2	304
71	Harnessing High Density Lipoproteins to Block Transforming Growth Factor Beta and to Inhibit the Growth of Liver Tumor Metastases. <i>PLoS ONE</i> , 2014, 9, e96799.	1.1	12
72	Histone deacetylase inhibitor-temozolomide co-treatment inhibits melanoma growth through suppression of Chemokine (C-C motif) ligand 2-driven signals. <i>Oncotarget</i> , 2014, 5, 4516-4528.	0.8	29

#	ARTICLE	IF	CITATIONS
73	Extracellular adenosine metabolism in immune cells in melanoma. <i>Cancer Immunology, Immunotherapy</i> , 2014, 63, 1073-1080.	2.0	53
74	Novel insights into exosome-induced, tumor-associated inflammation and immunomodulation. <i>Seminars in Cancer Biology</i> , 2014, 28, 51-57.	4.3	63
75	CTLA-4 and PD-L1 Checkpoint Blockade Enhances Oncolytic Measles Virus Therapy. <i>Molecular Therapy</i> , 2014, 22, 1949-1959.	3.7	249
76	Myeloid-derived suppressor cells in malignant melanoma. <i>JDDG - Journal of the German Society of Dermatology</i> , 2014, 12, 1021-1027.	0.4	44
77	Myeloide Suppressorzellen (MDSC) beim malignen Melanom. <i>JDDG - Journal of the German Society of Dermatology</i> , 2014, 12, 1021-1027.	0.4	14
78	Body Fluid Exosomes Promote Secretion of Inflammatory Cytokines in Monocytic Cells via Toll-like Receptor Signaling. <i>Journal of Biological Chemistry</i> , 2013, 288, 36691-36702.	1.6	203
79	Cyclophosphamide Promotes Chronic Inflammation-Dependent Immunosuppression and Prevents Antitumor Response in Melanoma. <i>Journal of Investigative Dermatology</i> , 2013, 133, 1610-1619.	0.3	91
80	Tumor Microenvironment and Myeloid-Derived Suppressor Cells. <i>Cancer Microenvironment</i> , 2013, 6, 169-177.	3.1	112
81	Low-dose gemcitabine depletes regulatory T cells and improves survival in the orthotopic Panc02 model of pancreatic cancer. <i>International Journal of Cancer</i> , 2013, 133, 98-107.	2.3	138
82	Ret transgenic mouse model of spontaneous skin melanoma: focus on regulatory T cells. <i>Pigment Cell and Melanoma Research</i> , 2013, 26, 457-463.	1.5	9
83	Antitumor Effect of Paclitaxel Is Mediated by Inhibition of Myeloid-Derived Suppressor Cells and Chronic Inflammation in the Spontaneous Melanoma Model. <i>Journal of Immunology</i> , 2013, 190, 2464-2471.	0.4	195
84	ChemolmmunoModulation: Focus on Myeloid Regulatory Cells. , 2013, , 603-619.		0
85	T-Cell Mediated Immune Responses Induced in ret Transgenic Mouse Model of Malignant Melanoma. <i>Cancers</i> , 2012, 4, 490-503.	1.7	14
86	New strategies for melanoma immunotherapy. <i>Oncolmmunology</i> , 2012, 1, 765-767.	2.1	5
87	Regulatory T Cells Stimulate B7-H1 Expression in Myeloid-Derived Suppressor Cells in ret Melanomas. <i>Journal of Investigative Dermatology</i> , 2012, 132, 1239-1246.	0.3	131
88	Application of paclitaxel in low non-cytotoxic doses supports vaccination with melanoma antigens in normal mice. <i>Journal of Immunotoxicology</i> , 2012, 9, 275-281.	0.9	52
89	Comment on "Adenosinergic Regulation of the Expansion and Immunosuppressive Activity of CD11b+Gr1+ Cells". <i>Journal of Immunology</i> , 2012, 188, 2929-2930.	0.4	11
90	Paclitaxel promotes differentiation of myeloid-derived suppressor cells into dendritic cells in vitro in a TLR4-independent manner. <i>Journal of Immunotoxicology</i> , 2012, 9, 292-300.	0.9	124

#	ARTICLE	IF	CITATIONS
91	Characterization and longitudinal monitoring of melanoma growth in ret-transgenic mice using a single-sequence MRI protocol. <i>Experimental Dermatology</i> , 2012, 21, 837-841.	1.4	0
92	Tumor-Infiltrating Monocytic Myeloid-Derived Suppressor Cells Mediate CCR5-Dependent Recruitment of Regulatory T Cells Favoring Tumor Growth. <i>Journal of Immunology</i> , 2012, 189, 5602-5611.	0.4	341
93	Melanoma-induced immunosuppression and its neutralization. <i>Seminars in Cancer Biology</i> , 2012, 22, 319-326.	4.3	106
94	Immunosuppression in the tumor microenvironment: Where are we standing?. <i>Seminars in Cancer Biology</i> , 2012, 22, 273-274.	4.3	7
95	Overcoming immunosuppression in the melanoma microenvironment induced by chronic inflammation. <i>Cancer Immunology, Immunotherapy</i> , 2012, 61, 275-282.	2.0	57
96	Chronic inflammation promotes myeloid-derived suppressor cell activation blocking antitumor immunity in transgenic mouse melanoma model. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 17111-17116.	3.3	303
97	Activation of p38 Mitogen-Activated Protein Kinase Drives Dendritic Cells to Become Tolerogenic in <i>Ret</i> Transgenic Mice Spontaneously Developing Melanoma. <i>Clinical Cancer Research</i> , 2009, 15, 4382-4390.	3.2	70
98	Skin Melanoma Development in ret Transgenic Mice Despite the Depletion of CD25+Foxp3+ Regulatory T Cells in Lymphoid Organs. <i>Journal of Immunology</i> , 2009, 183, 6330-6337.	0.4	55
99	Effect of artesunate on immune cells in ret-transgenic mouse melanoma model. <i>Anti-Cancer Drugs</i> , 2009, 20, 910-917.	0.7	29
100	Melanoma-Specific Memory T Cells Are Functionally Active in <i>Ret</i> Transgenic Mice without Macroscopic Tumors. <i>Cancer Research</i> , 2008, 68, 9451-9458.	0.4	60
101	Melanoma-Reactive T Cells in the Bone Marrow of Melanoma Patients: Association with Disease Stage and Disease Duration. <i>Cancer Research</i> , 2006, 66, 5997-6001.	0.4	30
102	Specifically activated memory T cell subsets from cancer patients recognize and reject xenotransplanted autologous tumors. <i>Journal of Clinical Investigation</i> , 2004, 114, 67-76.	3.9	101
103	Bone marrow as a priming site for T-cell responses to blood-borne antigen. <i>Nature Medicine</i> , 2003, 9, 1151-1157.	15.2	301